Id |
Subject |
Object |
Predicate |
Lexical cue |
T523 |
0-63 |
Sentence |
denotes |
Table 1 Summary of the main evidence emerging from the review. |
T524 |
64-79 |
Sentence |
denotes |
- Key-Messages |
T525 |
80-356 |
Sentence |
denotes |
Epidemiology The most common chronic preexisting diseases in deceased COVID-19 patients were diabetes mellitus, COPD, arterial hypertension, atrial fibrillation, chronic kidney disease (CKD), active cancer within the previous 5 years, ischemic heart disease and obesity [19]. |
T526 |
357-436 |
Sentence |
denotes |
CKD was present in more than 20% of the deceased patients due to COVID-19 [20]. |
T527 |
437-647 |
Sentence |
denotes |
Pathophysiology SARS-CoV-2 invades the target cells through a multi-step process that involves cell internalization through interaction with the ACE-2 receptor and priming by the cell protease TMPRSS2 [35,62]. |
T528 |
648-809 |
Sentence |
denotes |
The spike glycoprotein receptor binding domain (RBD) has biomolecular characteristics that are probably responsible for the greater diffusion of SARS-CoV-2 [42]. |
T529 |
810-944 |
Sentence |
denotes |
The renal damage observed in COVID-19 patients is the result of complex mechanisms induced directly and indirectly by SARS-CoV-2 [35]. |
T530 |
945-1110 |
Sentence |
denotes |
The two main pathophysiological mechanisms of kidney damage are direct cytopathic effect of SARS-CoV-2 on renal epithelial cells and cytokine storm syndrome [64,71]. |
T531 |
1111-1318 |
Sentence |
denotes |
Hypoxia, persistent hypotension, rhabdomyolysis, over activation of the coagulation cascade and impairment of microcirculation play a role in the predisposition to the development of acute renal damage [64]. |
T532 |
1319-1453 |
Sentence |
denotes |
Histopathology SARS-CoV-2 infection induces acute tubular necrosis through direct cytotoxicity and in immune mediated damage [62,63]. |
T533 |
1454-1507 |
Sentence |
denotes |
Light microscopy: acute renal proximal tubule injury. |
T534 |
1508-1610 |
Sentence |
denotes |
Immunohistochemistry: viral nucleocapsid protein into the renal tubular cells of the infected tissues. |
T535 |
1611-1766 |
Sentence |
denotes |
Transmission electron microscopy: viral inclusion bodies in a peritubular space and viral particles in endothelial cells of the glomerular capillary loops. |
T536 |
1767-1946 |
Sentence |
denotes |
Clinical Features COVID-19 patients with elevated baseline serum creatinine are more likely to be admitted to the intensive care unit and to undergo mechanical ventilation [106]. |
T537 |
1947-2020 |
Sentence |
denotes |
Kidney disease on admission is a higher risk of negative prognosis [106]. |
T538 |
2021-2113 |
Sentence |
denotes |
COVID-19 patients with AKI had ~5.3 times mortality risk higher than those without AKI [25]. |
T539 |
2114-2191 |
Sentence |
denotes |
The incidence of AKI in the overall cohort was in a range of 4.7–7.5% [8,15]. |
T540 |
2192-2428 |
Sentence |
denotes |
Dialysis patients have a higher rate of contracting SARS compared with the one of the general population, but both the degree of disease severity and the mortality rate of the dialysis group were similar to the general population [113]. |
T541 |
2429-2566 |
Sentence |
denotes |
SARS-CoV-2 was detected in peritoneal fluid; peritoneal dialysis patients have a higher mortality rate than the general population [119]. |
T542 |
2567-2810 |
Sentence |
denotes |
Kidney transplant patients have a higher mortality rate than the general population; the clinical manifestations were similar to those reported for the general population, more than half of the patients were successfully discharged home [119]. |
T543 |
2811-3146 |
Sentence |
denotes |
Management The diffusion of hygienic-behavioral rules among nephropathic patients and the preventive measures implemented in the various nephrological centers have proven effective in containing the diffusion of COVID-19 among patients with chronic kidney disease (on dialysis and non-dialysis) and transplanted kidney patients [137]. |
T544 |
3147-3201 |
Sentence |
denotes |
There is no vaccine and therapy specific for COVID-19. |
T545 |
3202-3270 |
Sentence |
denotes |
Most of vaccine candidates are still in the preclinical phase [149]. |
T546 |
3271-3494 |
Sentence |
denotes |
Chronic renal failure patients receive the same therapeutic protocols as the general population; these include antiviral drugs, tocilizumab, low molecular weight heparin, hydroxychloroquine (recently stopped by AIFA) [150]. |
T547 |
3495-3559 |
Sentence |
denotes |
Interferons have also been proposed as a possible therapy [158]. |